# Parabilis Medicines, Inc. Common Stock (PBLS)

> Parabilis Medicines, Inc. Common Stock (PBLS) trades at $26.77 (-5.24%) as of 4:02:15 AM EST on Nov 19, 2026, +5.13% over the past month. Market cap is $3.57B, with 8.3 days to cover in short interest.

Canonical: https://massive.com/quote/pbls
Data as of: 2026-11-19T09:02:15.306Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$26.77** -1.48 (-5.24%)
As of 4:02:15 AM EST on Nov 19, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Parabilis Medicines, Inc. Common Stock (PBLS) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.78% |
| 1W | -3.98% |
| 1M | +5.13% |
| YTD | -9.91% |
| 1Y | -9.91% |
| 52-wk range | $22.66 – $42.49 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for PBLS: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $27.70 – $29.26 |
| Open | $28.22 |
| Prev close | $28.25 |
| Volume | 602.37K |
| Market cap | $3.57B |
| Shares out | 125.26M |

## Insider trading

[Parabilis Medicines, Inc. Common Stock (PBLS) insider trading](https://massive.com/quote/pbls/insider-trading.md): open-market Form 4 buys and sells by Parabilis Medicines, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Parabilis Medicines, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 12, 2026, Parabilis Medicines, Inc. (the "Company") announced its financial results and business highlights for the quarter ended September 30, 2026.”
- Nov 5, 2026 · Lease agreement
  “On October 30, 2026, Parabilis Medicines, Inc. and LS 400/500 CDP, LLC entered into a Third Amendment of Lease, which amends the Lease regarding the Company's corporate headquarters located at 30 Acorn Park Drive, Cambridge, Massachusetts. The Amendment provides for an expansion, beginning on January 1, 2028, of the leased space by a total of 33,525 square feet at 20 Acorn Park Drive, an extension of the lease term through December 31, 2037, and options for further five-year extensions.”
- Sep 2, 2026 · Executive compensation change
  “In connection with his departure from the Company, Dr. Benzaghou will receive severance benefits pursuant to the terms of his employment agreement with the Company.”
- Aug 25, 2026 · Executive compensation change
  “In accordance with the Company's compensation program for non-employee directors, Mr. Tendler received an equity award consisting of a stock option to purchase 20,294 shares of the Company's common stock at an exercise price of $39.36 per share. The option award will vest in thirty-six substantially equal monthly installments over three years from the date of grant... Mr. Tendler will also receive an annual retainer of $40,000 for Board service and $7,500 for Science & Technology Committee service, each to be paid quarterly in arrears.”
- Aug 13, 2026 · Investor presentation
  “On August 13, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others from time to time and made the presentation available on the investor relation page of the Company's website at https://parabilismed.com/. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.”

## PBLS short interest

How heavily PBLS is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.3 |
| Short interest | 11.05M |
| Avg volume | 1.33M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## PBLS news

The latest news and headlines about Parabilis Medicines, Inc. Common Stock (PBLS).

- [Does Parabilis Medicines (PBLS) Have the Potential to Rally 44.11% as Wall Street Analysts Expect?](https://www.zacks.com/stock/news/3031137/does-parabilis-medicines-pbls-have-the-potential-to-rally-44-11-as-wall-street-analysts-expect?cid=CS-ZC-FT-fundamental_analysis|consensus_price_target-3031137) · Zacks Investment Research · Nov 17, 2026 · positive sentiment
- [Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors](https://www.globenewswire.com/news-release/2026/10/24/3387680/0/en/parabilis-medicines-presents-updated-phase-1-2-data-for-zolucatetide-demonstrating-compelling-efficacy-and-favorable-safety-and-tolerability-profile-in-patients-with-desmoid-tumors.html) · GlobeNewswire Inc. · Oct 24, 2026 · positive sentiment
- [Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors](https://www.globenewswire.com/news-release/2026/08/25/3350317/0/en/parabilis-medicines-appoints-accomplished-drug-development-leader-craig-l-tendler-m-d-to-board-of-directors.html) · GlobeNewswire Inc. · Aug 25, 2026 · positive sentiment
- [Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?](https://www.fool.com/investing/2026/06/12/parabilis-soared-58-in-the-biggest-biotech-ipo-on/?source=iedfolrf0000001) · The Motley Fool · Jun 12, 2026 · neutral sentiment
- [Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares](https://www.benzinga.com/pressreleases/26/06/g53155429/parabilis-medicines-announces-closing-of-upsized-initial-public-offering-including-full-exercise-o?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Jun 11, 2026 · positive sentiment

## About Parabilis Medicines, Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| IPO | $20.00 on Jun 10, 2026 |

[Parabilis Medicines IPO page](https://massive.com/quote/pbls/ipo.md)

[Company website](https://www.parabilismed.com)

## FAQ

### What is the Parabilis Medicines, Inc. Common Stock (PBLS) stock price today?

Parabilis Medicines, Inc. Common Stock (PBLS) is trading at $26.77 (-5.24% on the day) as of 4:02:15 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Parabilis Medicines, Inc. Common Stock?

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases.

### What is the short interest in PBLS?

As of Oct 30, 2026, PBLS has 11.05M shares short and 8.3 days to cover.

### What exchange is PBLS listed on?

Parabilis Medicines, Inc. Common Stock (PBLS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time PBLS quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=PBLS`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Parabilis Medicines, Inc. Common Stock (PBLS) insider trading](https://massive.com/quote/pbls/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
